Physician

Charles Shingirai Jere, MD

According to 2025 Medicare claims, Charles Jere, MD (NPI: 1578730867) practices nephrology in the Rocky Mount, NC market, with the plurality of this provider's patient population coming from Nash, NC. This provider's primary affiliated billing organization is BOICE-WILLIS CLINIC PA (NPI: 1699722389; TIN: 561025986) and primary practice location at 27801-6972. Jere is affiliated with the The Accountable Care Organization, Ltd. (ACO ID: A2098), participating under the MSSP model.

Jere's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 432 traditional Medicare patients, billed 1,663 HCPCS/CPT codes, and received $163,257 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,231 prescription claims across 325 beneficiaries totaling $773,690 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). 2021 DME data shows 27 claims. Open Payments data shows 3 records totaling $42. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $712,544 to $163,257. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $2,177,526 to $773,690. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,150	16,411	$712,544
2016	1,081	17,733	$524,378
2017	1,117	10,973	$474,988
2018	1,184	13,813	$588,822
2019	1,186	8,328	$534,046
2020	960	11,882	$522,072
2021	828	5,474	$428,531
2022	581	2,091	$271,689
2023	438	1,521	$169,273
2024	432	1,663	$163,257

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	545	5,533	$2,177,526
2016	475	4,530	$1,638,877
2017	440	3,665	$1,016,123
2018	453	3,371	$660,525
2019	478	2,986	$622,550
2020	452	3,106	$661,107
2021	353	2,359	$495,241
2022	324	1,955	$634,315
2023	321	2,304	$829,003
2024	325	2,231	$773,690

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	85	$3,314
2016	N/R	90	$3,744
2017	N/R	54	$2,450
2018	N/R	77	$6,051
2019	N/R	37	$1,943
2020	N/R	37	$1,312
2021	N/R	27	$811
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	94	103	$129
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	132	222	$85
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	172	413	$58
90935	Hemodialysis procedure with physician evaluation	50	96	$52
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	127	208	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	112	3,588	$366,529
Sevelamer Carbonate	Sevelamer Carbonate	297	9,735	$64,450
Farxiga	Dapagliflozin Propanediol	77	2,534	$46,208
Veltassa	Patiromer Calcium Sorbitex	51	1,656	$43,127
Procrit	Epoetin Alfa	19	532	$41,510

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$42	Aurinia Pharma U.S., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Shingirai Jere, MD?

Tedicare shows public-source Medicare data for Charles Shingirai Jere, MD (NPI 1578730867), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Shingirai Jere, MD have ACO affiliation data?

Charles Shingirai Jere, MD is shown with ACO affiliation data for The Accountable Care Organization, Ltd. (MSSP, ACO ID A2098).

What billing organization is linked to Charles Shingirai Jere, MD?

Charles Shingirai Jere, MD is linked to BOICE-WILLIS CLINIC PA (billing NPI 1699722389) in the available physician profile data.

Does Charles Shingirai Jere, MD have Open Payments data?

Charles Shingirai Jere, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.